Evidence map›Paper›PMID 38575891›Full record

ArticleBMC complementary medicine and therapies2024

Therapeutic effect of curcumin nanoemulsion on cystic echinococcosis in BALB/c mice: a computerized tomography (CT) scan and histopathologic study evaluation.

Mohamad Ghanimatdan, Seyed Mahmoud Sadjjadi, Fattaneh Mikaeili, Aref Teimouri, Seyed Hamed Jafari, Amin Derakhshanfar, Saeideh Hashemi-Hafshejani

Open access · goldAbstract read
In one paragraph

Article in BMC complementary medicine and therapies, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Mohamad GhanimatdanDepartment of Parasitology and Mycology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID https://orcid.org/0000-0003-1072-9682
Seyed Mahmoud SadjjadiDepartment of Parasitology and Mycology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. sadjjadi316@gmail.com.ORCID https://orcid.org/0000-0002-0041-5906
Fattaneh MikaeiliDepartment of Parasitology and Mycology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID https://orcid.org/0000-0002-6006-5485
Aref TeimouriDepartment of Parasitology and Mycology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID https://orcid.org/0000-0002-1772-8917
Seyed Hamed JafariDepartment of Radiology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID https://orcid.org/0000-0001-5364-2566
Amin DerakhshanfarDepartment of Comparative Biomedical Sciences, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID https://orcid.org/0000-0002-8007-9446
Saeideh Hashemi-HafshejaniDepartment of Parasitology and Mycology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0002-7705-6729
Shiraz University of Medical Sciences · IRIran University of Medical Sciences · IR

Funding

Shiraz University of Medical Sciences 24463
6 · The paper itself

Abstract

backgroundThis study aimed to determine the therapeutic efficacy of curcumin nanoemulsion (CUR-NE) in mice infected with Echinococcus granulosus sensu stricto protoscoleces.

methodsForty-two inbred BALB/c mice were divided into seven groups of six animals each. Six groups were inoculated intra-peritoneally with 1500 viable E. granulosus protoscoleces, followed for six months and used as infected groups. The infected groups were named as: CEI1 to CEI6 accordingly. The 7th group was not inoculated and was named cystic echinococcosis noninfected group (CENI7). CEI1 and CEI2 groups received 40 mg/kg/day and 20 mg/kg/day curcumin nanoemulsion (CUR-NE), respectively. CEI3 received nanoemulsion without curcumin (NE-no CUR), CEI4 received curcumin suspension (CUR-S) 40 mg/kg/day, CEI5 received albendazole 150 mg/kg/day and CEI6 received sterile phosphate-buffered saline (PBS). CENI7 group received CUR-NE 40 mg/kg/day. Drugs administration was started after six months post-inoculations of protoscoleces and continued for 60 days in all groups. The secondary CE cyst area was evaluated by computed tomography (CT) scan for each mouse before treatment and on the days 30 and 60 post-treatment. The CT scan measurement results were compared before and after treatment. After the euthanasia of the mice on the 60th day, the cyst area was also measured after autopsy and, the histopathological changes of the secondary cysts for each group were observed. The therapeutic efficacy of CUR-NE in infected groups was evaluated by two methods: CT scan and autopsied cyst measurements.

resultsSeptal calcification in three groups of infected mice (CEI1, CEI2, and CEI4) was revealed by CT scan. The therapeutic efficacy of CUR-NE 40 mg/kg/day (CEI1 group) was 24.6 ± 26.89% by CT scan measurement and 55.16 ± 32.37% by autopsied cysts measurements. The extensive destructive effects of CUR-NE 40 mg/kg/day (CEI1 group) on the wall layers of secondary CE cysts were confirmed by histopathology.

conclusionThe current study demonstrated a significant therapeutic effect of CUR-NE (40 mg/kg/day) on secondary CE cysts in BALB/c mice. An apparent septal calcification of several cysts revealed by CT scan and the destructive effect on CE cysts observed in histopathology are two critical key factors that suggest curcumin nanoemulsion could be a potential treatment for cystic echinococcosis.

Indexed as

CurcuminCystsEchinococcosisAnimalsMiceMice, Inbred BALB CTomographyCurcuminCalcificationCT scanCurcumin nanoemulsionCystic echinococcosisEchinococcus granulosusIn vivoTherapeutic efficacy

Identifiers

PMID38575891
PMCPMC10993536
OpenAlexW4393941352

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.